Leerink Partnrs Weighs in on Vaxcyte FY2029 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Vaxcyte in a research note issued on Sunday, January 12th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $2.42 for the year. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Several other brokerages have also recently issued reports on PCVX. Needham & Company LLC reiterated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $145.71.

Vaxcyte Stock Performance

PCVX opened at $81.17 on Tuesday. Vaxcyte has a 52-week low of $58.10 and a 52-week high of $121.06. The stock has a market capitalization of $10.12 billion, a PE ratio of -17.65 and a beta of 0.98. The stock’s 50 day moving average price is $89.69 and its 200-day moving average price is $93.54.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the firm earned ($0.91) earnings per share.

Insider Activity at Vaxcyte

In other news, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total value of $457,450.00. Following the completion of the transaction, the senior vice president now owns 28,697 shares in the company, valued at $2,625,488.53. The trade was a 14.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $21,968,226. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,732 shares of company stock valued at $11,730,787 in the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently modified their holdings of PCVX. Harbor Capital Advisors Inc. raised its position in Vaxcyte by 15.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 74,907 shares of the company’s stock worth $6,132,000 after acquiring an additional 10,243 shares during the period. Diversified Trust Co bought a new position in Vaxcyte in the 4th quarter worth $1,433,000. Everence Capital Management Inc. purchased a new position in Vaxcyte during the fourth quarter valued at $301,000. Principal Financial Group Inc. grew its holdings in Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock valued at $6,022,000 after purchasing an additional 34,287 shares during the period. Finally, Lord Abbett & CO. LLC increased its position in Vaxcyte by 26.9% in the third quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company’s stock worth $35,701,000 after buying an additional 66,183 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.